The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for cenegermin (recombinant human nerve growth factor) (JACE Pharma Pty Ltd)
Active ingredients
cenegermin (recombinant human nerve growth factor)
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults
Therapeutic area
Ophthalmology